Seller record · Telehealth service

NativeMed

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 1 of 8 criteria. S5, analytical documentation: No certificate of analysis or lot document is published on the product pages, the pharmacy services page or the policies.

At a glance

NativeMedTelehealth service

7/8criteria passed
Price
Semaglutide from $149 a month on a 3-month plan, tirzepatide from $183
Sells
compounded semaglutide injectable, compounded tirzepatide injectable, and 2 more
FDA letters
1 on file
Visit NativeMedSee all eight dispositions

Telehealth service. Passes 7 of 8 criteria. Recorded against Standard v1.1.

A Florida telehealth service selling compounded semaglutide and tirzepatide, NAD+ and sermorelin injections on monthly and three-month plans at one price for every dose. It names its partner pharmacy with a street address, and an FDA warning letter addressed it in June 2026.

Operating entity NativeMed, LLC

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSNativeMed's website; NativeMed's pharmacy services page
S2Prescription gatingPASSNativeMed's sign-up site; NativeMed's semaglutide product page
S3Pharmacy identificationPASSNativeMed's pharmacy services page
S4Compounding disclosurePASSNativeMed's semaglutide product page; NativeMed's tirzepatide product page; NativeMed's pharmacy services page
S5Analytical documentationFAILNativeMed's pharmacy services page; NativeMed's products page
S6Business addressPASSNativeMed's terms of use page; NativeMed's privacy policy; NativeMed's contact page
S7Price disclosurePASSNativeMed's semaglutide product page; NativeMed's tirzepatide product page; NativeMed's NAD+ page; NativeMed's sermorelin page
S8Enforcement statusPASSFDA's website; FDA warning letter 728287

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed healthcare provider reviews the patient questionnaire and decides whether treatment is medically appropriate before a prescription is sent to a partner pharmacy.Source: NativeMed's website; NativeMed's pharmacy services page.
S2PASSThe start button on the semaglutide page opens an online visit whose first screen asks the buyer's weight loss goal.Source: NativeMed's sign-up site; NativeMed's semaglutide product page.
S3PASSThe pharmacy services page names VialsRx at 16402 FM 2920, Building D, Tomball, TX 77377 as the partner pharmacy that may fill a prescription.Source: NativeMed's pharmacy services page.
S4PASSThe product pages name the medication as compounded semaglutide and compounded tirzepatide, and the footer on every page states that compounded medications are not approved by FDA.Source: NativeMed's semaglutide product page; NativeMed's tirzepatide product page; NativeMed's pharmacy services page.
S5FAILNo certificate of analysis or lot document is published on the product pages, the pharmacy services page or the policies.Source: NativeMed's pharmacy services page; NativeMed's products page.
S6PASSNativeMed, LLC at 66 W Flagler Street, Suite 900, Miami, FL 33130, printed in the terms of use and the privacy policy, with the same street on the contact page.Source: NativeMed's terms of use page; NativeMed's privacy policy; NativeMed's contact page.
S7PASSCompounded semaglutide at $179 a month with a first month at $159, or $149 a month on a 3-month plan billed $447, and compounded tirzepatide at $259 a month with a first month at $199, or $183 a month billed $549, the same price at every dose. The NAD+ injection at $189 a month or $160 on a 3-month plan, and sermorelin at $159 a month or $149.Source: NativeMed's semaglutide product page; NativeMed's tirzepatide product page; NativeMed's NAD+ page; NativeMed's sermorelin page.
S8PASSFDA warning letter 728287, June 2026, names NativeMed LLC dba NativeMed at the Miami street address the site prints, alleging that pictured labels presented NativeMed as the compounder of its tirzepatide and that a claim of the same active ingredient as Ozempic and Wegovy implied FDA approval. No FDA action has halted the business, and the seller still trades.Source: FDA's website; FDA warning letter 728287.

Products shown on the seller's own pages at the recorded date: compounded semaglutide injectable, compounded tirzepatide injectable, NAD+ injection, sermorelin injectable.

Other sellers of the same products

Who sells semaglutideWho sells tirzepatideWho sells sermorelinWho sells NAD+

Enforcement documents on file: 1 warning letter

FDA warning letter 728287, issued June 2026, to NativeMed LLC dba NativeMedPictured labels identify NativeMed as the compounder of tirzepatide products when it is not, and a claim of the same active ingredient as Ozempic and Wegovy represents compounded semaglutide as FDA-approved or evaluated for safety and effectiveness.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Visit NativeMed

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.